BioMarin Pharmaceutical Inc. (BVMF:B1MR34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 49.84B -27.0% |
| Revenue (ttm) | 16.91B +9.9% |
| Net Income | 1.40B -48.7% |
| EPS | 7.29 -48.2% |
| Shares Out | n/a |
| PE Ratio | 35.55 |
| Forward PE | 9.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 603 |
| Open | 131.96 |
| Previous Close | n/a |
| Day's Range | 131.96 - 131.96 |
| 52-Week Range | 131.06 - 175.00 |
| Beta | 0.23 |
| RSI | 33.05 |
| Earnings Date | Apr 24, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value…
BioMarin price target raised to $116 from $104 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $116 from $104 and keeps a Buy rating on the shares. The firm said 1Q26 earnings delivered…
BioMarin price target lowered to $119 from $120 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $120 and keeps an Overweight rating on the shares. Q1 reinforces a near-term transition…
BioMarin price target raised to $120 from $110 at Evercore ISI
Evercore ISI raised the firm’s price target on BioMarin (BMRN) to $120 from $110 and keeps an Outperform rating on the shares.
BioMarin price target lowered to $82 from $94 at Bernstein
Bernstein analyst William Pickering lowered the firm’s price target on BioMarin (BMRN) to $82 from $94 and keeps an Outperform rating on the shares. The firm notes revenue beat by…
BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026
Amicus acquisition closed, boosting 2026 revenue growth outlook to 20% and expanding the portfolio with Galafold and Pombiliti/Opfolda. Strong Q1 demand for enzyme therapies and Voxzogo, especially among young children, supports raised guidance. Over half of 2026 revenues expected in H2.
BioMarin Reports First Quarter 2026 Financial and Operating Results
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt...
BioMarin announces new research from studies of Voxzogo
BioMarin (BMRN) Pharmaceutical announced new research from studies of Voxzogo in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone ...
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with ...
BioMarin completes acquisition of Amicus Therapeutics
BioMarin Pharmaceutical(BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash transaction for a total equity value o...
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to ...
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf...
BioMarin resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Sean Laaman resumed coverage of BioMarin (BMRN) with an Overweight rating with a price target of $120, up from $98. The Amicus (FOLD) acquisition does not eliminate…
BioMarin appoints Ian Clark as Chair of the Board
BioMarin (BMRN) Pharmaceutical said that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company’s Annual Meeting of Stockholders…
BioMarin Announces Board Leadership Transition
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
BioMarin (BMRN) announced Monday the discontinuation of three Voxzogo Phase 2 studies in Turner Syndrome, SHOX-difficiency, and ACAN-difficiency, due to several cases of Slipped Capital Femoral Epiphy...
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, se...
BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
BioMarin (BMRN) announced its decision to discontinue dosing and enrollment in its Phase 2 trials for Voxzogo in Turner syndrome, SHOX-deficiency and aggrecan-deficiency following the occurrence of se...
BioMarin’s Voxzogo shows impact in pediatric achondroplasia
BioMarin (BMRN) announced positive new data from studies of Voxzogo – vosoritide – in children with achondroplasia in ongoing clinical trials and real-world studies. The latest findings reinforce the ...
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, buildin...
BioMarin Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 13% in 2025, with strong performance from Voxzogo and enzyme therapies. Key 2026 catalysts include major phase III readouts, the Amicus acquisition, and new product launches. Commercial focus remains on expanding access, managing competition, and leveraging operational synergies.
BioMarin price target lowered to $85 from $97 at BofA
BofA lowered the firm’s price target on BioMarin (BMRN) to $85 from $97 and keeps a Buy rating on the shares. The firm, which updated its outlook for the pro-forma…
BioMarin Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Revenue grew 13% in 2025, with high single-digit growth expected in 2026. Key pipeline milestones include phase III data for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency. The Amicus acquisition is set to expand the portfolio and drive accretion by 2027.
BioMarin Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
A strategic refresh has driven recent acquisitions and a focus on pipeline expansion, with 2026 guidance reflecting competitive and revenue headwinds but projecting solid growth in enzyme therapies and skeletal conditions. Key products like Voxzogo and Palynziq are positioned for continued growth, while new clinical milestones and the Amicus acquisition are expected to drive long-term value.
BioMarin price target raised to $105 from $80 at Barclays
Barclays raised the firm’s price target on BioMarin (BMRN) to $105 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Amicus…